Publication | Open Access
Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
40
Citations
22
References
2022
Year
| Year | Citations | |
|---|---|---|
Page 1
Page 1